Zai Lab Limited
0.0 %
29.49 %
Yet to be announced
Company Overview
Zai Lab Limited is a commercial-stage biopharmaceutical company based in China and the United States. The company focuses on developing and commercializing innovative medicines for oncology, autoimmune disorders, infectious diseases, and neurological disorders. They operate through partnerships with global pharmaceutical companies to in-license and develop drugs for Greater China and other Asian markets.
Revenue Sources
Based on SEC filings and company reports, Zai Lab's revenue comes primarily from the sale of pharmaceutical products and licensing agreements. Their business model focuses on developing and commercializing medicines, which are halal activities. There is no evidence of revenue from prohibited sources.
Reliance on Interest
| Reporting Date | Total Revenue | Total Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2024 | $102.27m | $170.86m | - | $745,000 | 0.00% | 0.44% |
| June 30, 2024 | $100.5m | $177.06m | - | $492,000 | 0.00% | 0.28% |
| March 31, 2024 | $87.15m | $157.57m | - | $113,000 | 0.00% | 0.07% |
| Dec. 31, 2023 | $65.83m | $189.81m | - | - | 0.00% | 0.00% |
Looking at the last four quarters, interest expense ratios have been consistently low relative to total expenses. In the most recent quarter, interest expense represents only 0.44% of total expenses. The company appears to be primarily funded through equity rather than interest-bearing debt.
Operational Ethics
Zai Lab has significant operations in China and collaborates with Chinese institutions. While the company operates in China, there isn't clear evidence of direct material collaboration with the Chinese Communist Party. However, given the company's deep integration into the Chinese pharmaceutical sector and the nature of regulatory requirements in China, this aspect requires careful consideration.
Login to join the discussion